Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents

BACKGROUND: Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo‐HCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Faisal, Muhammad Salman, Hanel, Walter, Voorhees, Timothy, Li, Rui, Huang, Ying, Khan, Abdullah, Bond, David, Sawalha, Yazeed, Reneau, John, Alinari, Lapo, Baiocchi, Robert, Christian, Beth, Maddocks, Kami, Efebera, Yvonne, Penza, Sam, Saad, Ayman, Brammer, Jonathan, DeLima, Marcos, Jaglowski, Samantha, Epperla, Narendranath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134314/
https://www.ncbi.nlm.nih.gov/pubmed/36653918
http://dx.doi.org/10.1002/cam4.5631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134314/
https://www.ncbi.nlm.nih.gov/pubmed/36653918
http://dx.doi.org/10.1002/cam4.5631

Ejemplares similares